Press release
Apixaban Market Overview, Trends And Forecast 2024-2033
Apixaban Market Overview
As per the report, the apixaban market size has grown strongly in recent years. It will grow from $2.69 billion in 2023 to $2.92 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The apixaban market size is expected to see strong growth in the next few years. It will grow to $4.12 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%.
Download Free Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15979&type=smp
Impact Of Cardiovascular Disease Prevalence On Apixaban Market Growth
The rising prevalence of cardiovascular disease is expected to propel the growth of the apixaban market going forward. Cardiovascular disease encompasses a range of conditions affecting the heart and blood vessels, including coronary artery disease, stroke, and heart failure. The rising prevalence of cardiovascular disease is due to sedentary lifestyles, poor dietary habits, tobacco use, obesity, high blood pressure, diabetes, and aging populations. Apixaban is utilized in the management of cardiovascular disease by reducing the risk of blood clots by preventing conditions such as stroke, deep vein thrombosis, and pulmonary embolism. For instance, in January 2024, according to the American Heart Association, a US-based nonprofit organization, the number of deaths caused by cardiovascular diseases reached 931,578, an uptick of fewer than 3,000 fatalities compared to the 928,741 in 2023. Therefore, the rising prevalence of cardiovascular disease drives the growth of the apixaban market.
Rise Of Generic Apixaban Expands Access And Affordability
Major companies operating in the apixaban market are focusing on developing innovative products, such as generic anticoagulant medicine, to increase affordability and accessibility for patients while also expanding their market reach and competitiveness. A generic anticoagulant medicine is a drug that prevents blood clot formation by inhibiting various factors in the coagulation process, reducing the risk of stroke and other cardiovascular events. For instance, in October 2022, Tiefenbacher Pharmaceuticals, a Germany-based healthcare company, launched a generic version of Apixaban in Canada. This oral anticoagulant is used for prophylaxis post-elective hip or knee replacement, stroke prevention in atrial fibrillation, and treatment of deep vein thrombosis and pulmonary embolism, catering to a broad spectrum of thrombotic disorders. The company has developed 2.5 mg and 5 mg anticoagulant tablets in their Indian laboratories, to be distributed in Canada through a partnership with generic pharmaceutical companies, followed by a subsequent launch in additional global markets. This strategic move facilitates significant cost savings for international healthcare systems and enhances accessibility to life-improving treatments for millions of patients.
The apixaban market covered in this report is segmented -
1) By Dosage Form: Capsule, Tablets
2) By Application: Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=15979&type=discount
Major companies operating in the apixaban market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hetero Drugs Ltd, Eisai Co. Ltd, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd, Medichem S.A., Centaur Pharmaceuticals Pvt. Ltd., Simson Pharma Limited, OPOCRIN SPA, Pinnacle Life Sciences Private Limited
Contents of the report:
1. Executive Summary
2. Apixaban Market Report Structure
3. Apixaban Market Trends And Strategies
4. Apixaban Market - Macro Economic Scenario
5. Apixaban Market Size And Growth
…..
27. Apixaban Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Explore the report store to make a direct purchase of the report @
https://www.thebusinessresearchcompany.com/report/apixaban-global-market-report
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Apixaban Market Overview, Trends And Forecast 2024-2033 here
News-ID: 3582895 • Views: …
More Releases from The Business research company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Apixaban
Global Apixaban Prices Q2 2025: Chart, Analysis & Forecast
North America Apixaban Prices Movement Q2:
Apixaban Prices in USA:
In Q2 2025, apixaban prices in the USA reached 44,617 USD/MT in June. Prices rose steadily, supported by consistent demand for cardiovascular therapies, higher API production and compliance costs, and stable healthcare utilization. Generics moderated volatility, yet firm supply chains and sustained consumption maintained a controlled, input cost-driven price increase.
Get the Real-Time Prices Analysis: https://www.imarcgroup.com/apixaban-pricing-report/requestsample
Note: The analysis can be tailored to align…
Apixaban Market Analysis Current Landscape and Future Outlook
The Apixaban market is expected to grow at a CAGR of 6.2% between 2025 and 2035, driven by the rising prevalence of cardiovascular diseases, increasing awareness of stroke prevention, and the growing preference for direct oral anticoagulants (DOACs) over traditional blood thinners.
Apixaban Market Overview
Apixaban is a factor Xa inhibitor that is widely used for the prevention and treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and stroke…
Key Trend Reshaping the Apixaban Market in 2025: Rise Of Generic Apixaban Expand …
What market dynamics are playing a key role in accelerating the growth of the apixaban market?
The increase in cases of cardiovascular disease is anticipated to boost the expansion of the apixaban market. The term cardiovascular disease covers a variety of conditions that impact the heart and blood vessels, such as coronary artery disease, stroke, and heart failure. The escalation in cardiovascular diseases can be attributed to inactive lifestyles, poor nutrition,…
Primary Catalyst Driving Apixaban Market Evolution in 2025: Impact Of Cardiovasc …
What Is the Future Outlook for the Apixaban Market's Size and Growth Rate?
In the past few years, there has been significant growth in the apixaban market size. It is projected to ascend from $2.92 billion in 2024 to $3.19 billion in 2025, marking a compound annual growth rate (CAGR) of 9.2%. The growth observed in the historic period is due to factors such as the rising case of atrial fibrillation,…
Apixaban Market: Growth Dynamics, Trends, and Opportunities
Apixaban, an oral anticoagulant primarily used to prevent and treat blood clots, has become a cornerstone in modern medical practice. As an integral part of managing cardiovascular and thromboembolic disorders, its role in healthcare continues to expand. This article delves into the Apixaban market, covering its size, evolution, trends, growth drivers, and the increasing demand propelling its trajectory.
Market Size
Data Bridge Market Research analyses a growth rate in the global apixaban…
Apixaban Market Research Report Up to 2031
Visiongain has published a new report on Apixaban Market Report to 2031. Market is segmented By Dosage Form (Capsule, Tablet), By end user (Hospitals, Retail Pharmacies, Online Pharmacies, Others). Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report includes detailed Profiles of Leading Apixaban Companies. PLUS COVID-19 Recovery Scenarios.
Download Exclusive Sample of Report @ https://www.visiongain.com/report/apixaban-market/#download_sampe_div
The study covers detailed and insightful chapters on market overview, market…
